Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLGF

PLGF

Brief Information

Name:Placental Growth Factor
Target Synonym:PGFL,Placental Growth Factor-Like,SHGC-10760,D12S1900,PlGF-2,PIGF,Placenta growth factor,PlGF,PGF,Placental Growth Factor,Placental Growth Factor, Vascular Endothelial Growth Factor-Related Protein
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

PGF-H5256-ELISA
 PLGF ELISA

Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PlGF-1 Protein, Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).

PGF-H5255-MALS-HPLC
PLGF MALS images

The purity of Human PLGF-3 Protein, Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.

Synonym Name

PGF,PLGF,PlGF,PGFL,SHGC-10760

Background

Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Approved Momenta, Mylan Nv YESAFILI EU Myopia, Degenerative; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Complications; Macular Edema Viatris Ltd 2023-09-15 Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Approved Qilu Pharmaceutical Co Ltd Mainland China Macular Degeneration; Diabetic macular oedema Qilu Pharmaceutical Co Ltd 2023-12-13 Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
Aflibercept biosimilar (Amgen) ABP-938 Approved Amgen Inc PAVBLU United States Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema Amgen Inc 2024-08-23 Macular Edema; Wet Macular Degeneration; Vascular Diseases; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
Aflibercept BAY-865321; BAT-86-5321 Approved Regeneron Pharmaceuticals Inc, Bayer AG Eylea, 艾力雅 United States Macular Degeneration; Macular Edema Regeneron Pharmaceuticals Inc 2011-11-18 Wet Macular Degeneration; Corneal Neovascularization; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Retinopathy of Prematurity; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy; Macular Degeneration; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Drug-Related Side Effects and Adverse Reactions; Diabetic macular oedema; Retinitis Pigmentosa; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Choroid Diseases; Rectal Neoplasms; Diabetes Mellitus, Type 2; Glaucoma, Neovascular; Macular Edema; Cataract; Diabetes Mellitus, Type 1 Details
Aflibercept biosimilar (HEXAL/Sandoz) SOK-583A1; SOK583A1; SOK-583 Approved Sandoz, Hexal ENZEEVU, Afqlir United States Wet Macular Degeneration Sandoz Inc 2024-08-09 Retinal Diseases; Wet Macular Degeneration; Macular Degeneration Details
Aflibercept biosimilar (Celltrion) CT-P42 Approved Celltrion Inc Eydenzelt South Korea Wet Macular Degeneration; Diabetic macular oedema Celltrion Inc 2024-05-30 Wet Macular Degeneration; Diabetic macular oedema Details
Ziv-aflibercept BAY-865321; AVE-0005 Approved Regeneron Pharmaceuticals Inc, Sanofi Zaltrap United States Colorectal Neoplasms Sanofi-Aventis U.S. Llc 2012-08-03 Endometrial Neoplasms; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Astrocytoma; Gliosarcoma; Lung Neoplasms; Lymphoma; Metastatic breast cancer; Prostatic Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Glioma; Carcinoma, Neuroendocrine; Uterine Neoplasms; Fallopian Tube Neoplasms; Retinal Vein Occlusion; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Small Cell Lung Carcinoma; Skin Melanoma; Leukemia; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leiomyosarcoma; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Papillary; Ovarian Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Carcinoma, Ovarian Epithelial; L Details
Aflibercept biosimilar (Bioeq) FYB-203 Approved Formycon AG AHZANTIVE, Baiama United States Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Retinal Vein Occlusion; Macular Degeneration Formycon AG 2024-06-28 Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion Details
Aflibercept biosimilar (Samsung Bioepis) SB-15; AM003; SB15 Approved Samsung Bioepis Co Ltd OPUVIZ, Opuviz, AFILIVU United States Diabetic macular oedema; Macular Edema; Wet Macular Degeneration; Diabetic Retinopathy Samsung Bioepis Co Ltd 2024-05-20 Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aflibercept biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Macular Degeneration Details
Aflibercept biosimilar (Shilpa Biologicals) SBDM-03 Phase 3 Clinical Shilpa Biologicals Pvt Ltd Wet Macular Degeneration Details
Aflibercept Biosimilar(Rophibio) RBS-001 Phase 3 Clinical Rophibio Inc Wet Macular Degeneration; Macular Degeneration Details
Aflibercept Biosimilar (Alvotech Swiss) AVT-06; AVT-29 Phase 3 Clinical Alvotech Swiss Ag Vascular Diseases; Macular Degeneration Details
Aflibercept biosimilar (Mabwell) 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd Diabetic macular oedema Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Wet Macular Degeneration; Macular Degeneration Details
Anti-placental growth factor monoclonal antibody αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 Phase 2 Clinical Thrombogenics, Bioinvent International Ab Solid tumours; Retinal Telangiectasis; Ovarian Neoplasms; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Carcinoma, Hepatocellular; Diabetes Mellitus; Macular Degeneration Details
4D-150 4D-150 Phase 2 Clinical 4d Molecular Therapeutics Inc Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012; BA-1103 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Colorectal Neoplasms Details
PB-101 PB-101 Phase 1 Clinical Panolos Bioscience Inc Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular Details
EB-105 EB-105 Phase 1 Clinical Eluminex Biosciences (Suzhou) Ltd Diabetic macular oedema; Diabetic Retinopathy Details
Aflibercept biosimilar(Generium) GNR-098 Phase 1 Clinical Generium Pharmaceuticals Macular Degeneration Details
Aflibercept biosimilar (Zein Bioteccnology) Phase 1 Clinical Zein Bioteccnology Co Ltd Diabetic macular oedema Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message